VAN I know it went up last time but my indicators are flashing red on VMC-- GET OUT! Chart Events Bearishpattern detected Price Crosses Moving Average Short Term DOWN
Biden said last night he's going to rebuild the nation's roads and bridges. We hear that every 4 years. You're probably right lol.
It's funny two years ago I was in a meeting with a bunch of bankers and I told them the AirBnB IPO would be the top of the market... Consider this is took Apple it's whole professional life from that Apple 1 keyboard and suitcase till the i phone of today it took all that time from garage in Palo Alto to your back pocket, from the 1970's? to last year to become a Trillion dollar company. And in one short year they did it again! And what did they do in that year to deserve as much market cap growth as their entire history as a company? You tell me.
Berry Global Group Addresses Global Shortage Of Face Mask Materials To address the ever increasing demand for face mask material in the U.S., Berry has expanded its Meltex™ platform to add capacity in Waynesboro, VA. May 20, 2020 Last month, Berry Global Group, Inc. announced strategic initiatives to increase production of face mask materials. The initiatives include designating additional capacity for the production of face mask materials in North America and introducing a new material for face masks in Europe. With demand outpacing current supply for face mask filter media, the product development team at Berry responded to deliver innovative solutions in a matter of weeks to support the demand. These solutions include pivoting existing manufacturing assets and creating alternative materials for face masks. (Photo: Berry Global Group, Inc.) To address the ever increasing demand for face mask material in the U.S., Indiana-based Berry has expanded its proprietary Meltex™ platform to add meltblown capacity in Waynesboro, VA. This capacity was quickly converted from a pilot line into one which provides full commercial output. The line makes meltblown materials which are used in surgical-grade face masks along with N95 and N99 respirators. This added capacity supports the manufacturing of approximately 200 million face masks annually.
Up 5% today Stoney. Never short a stock making new highs brother. Its just the way it is. Calling tops is tough. You're way right, but you're also way early. I'll let you know when its time.
484 Often we look to insiders for incite into the workings of their company. Often these losers are to be mistrusted abusing the system and pocketing untold wealth while the regular man toils away. There are however certain companies that also give an accurate reflection of the economy and for those we must pay attention. I'm sure you guys all rememeber Lord Of The Rings and that scary little character Golub. Well this cat made so much doegh from that movie that he went on to form Golub Capital. Lets take a look inside--> Now I've read a lot of earnings reports in my time and I have to say none of them really caught me attention as being " uplifting " or particularly different, they all are the same.. Safe Harbor statement before turning over to CFO and then I'll wrap up by taking your questions before I fall asleep in my soup. But this Golub you know his style... he just stepped up and slammed it! -Let me start with two headlines. The first headline is that GBDC's results for fiscal Q3 were consistent with the estimates we filed on July 15. Adjusted net investment income per share was $0.28, adjusted EPS was $0.94 and NAV per share was $14.05. The second headline is that our fiscal Q3 results were strong. The portfolio generated solid adjusted net investment income and demonstrated strong resilient credit results, including the reversal of a meaningful portion of the unrealized losses that depressed performance in fiscal Q2. I'm going to start by reviewing key performance drivers for fiscal Q3 and then I'm going to go through GBDC's results for the quarter in detail with a lot of help from my colleagues on the phone. After that, we'll take your questions. --> Love it! Created two headlines himself and the second one was life is good! 1st headline jerks-- we did what we said 2nd headline idiots-- results were strong! Questions? You got to like this guys style. Slide 6 please. On Slide 6, we've outlined three themes beyond good underwriting that we believe drove GBDC's strong fiscal third quarter. First, the US economy began reopening sooner than expected; second, GBDC's portfolio companies generally performed better than expected, especially the ones in impacted sub-sectors; and third, our private equity sponsors have generally stepped up to support their portfolio companies. Let me elaborate on each of these three. First, the economy reopened faster than we expected. When we did our risk assessments in late March and April, our base case was a meaningful reopening by mid-summer. Our downside case was a bit after Labor Day and our upside case was the end of June. In fact, we saw substantial reopening in May. Now maybe Dr. Fauchi is right [Phonetic], and this was too soon from the standpoint of controlling COVID. But we believe the earlier reopening gave a substantial boost to many borrowers in GBDC's portfolio. Second theme within GBDC's portfolio in general, borrowers performed better than expected, especially those in COVID-impacted sub-sectors. You'll recall from our fiscal second quarter earnings presentation that we focused on five industry sub-sectors where we saw more risk of COVID impact; restaurants, dental care, eye care, fitness franchises and retail. -> Very concise and clear! In fiscal Q3, we're encouraged to see that many of GBDC's obligors in these industry sub-sectors performed better than expected. In general, most of GBDC's restaurant retail obligors found ways to stay open, to cut costs, to pivot, to emphasize takeout delivery curbside or Internet-based models. Some of the obligors in these industry sub-sectors actually posted same-store sales gains during the quarter. And our dental and eye care obligors who were closed for a period of time, have also in general opened stronger and better than we expected. --> This is really helpful because I live in NYC and there we are waiting for Snake Plissken to drop from the heavens and save us... (I've been using alot of movie references lately) Third theme, our private equity sponsors are generally stepping up to support their portfolio companies. We worried in March and April, at the beginning of COVID, that sponsors would have so many problem children that they wouldn't have bandwidth or sufficient capital to be able to address them. So far, those worries are not playing out. We're seeing sponsors contributing time, expertise, operating executives and in many cases capital. We think this reflects the strength of our borrowers, the strength of our sponsors and the strength of Golub Capital's relationships with those sponsors. --> Another important point. Now the flip side of this is the dirty banks are stealing homes again and all of that nonsense of buying cheap undervalued properties from struggling Americans who can't make their mortgage... But lets stick to the good stuff-- Golub Capital BDC (NASDAQ:GBDC) +1.1% as CEO David Golub buys 149,404 common shares for total transaction value of $1.89M. Over 80% of the portfolio at June 30 consisted of investments in industries we believe are relatively insulated from COVID-19, areas like enterprise software, business services, financial services and more. By the same token [Phonetic], less than 1% of the portfolio consisted of investments in sectors we now have been particularly hard hit by COVID-19 like airlines, entertainment, hotels, energy and others. Most of our proactive portfolio management has focused on the roughly 20% of the portfolio in industry sub-sectors we identified as less insulated from COVID-19. In another filing, Chairman Lawrence Golub bought 149,404 common shares for total transaction value of $1.89M. Lawrence Golub, Chairman and David Golub, CEO has collectively bought 923,268 common shares in the last 10 days.!!!!!!!!!! 10 days of buying... hummmmm. The stock has been $12 the entire time..... 1st Idea For Next Week is GBDC-$12.75
Idea #2-- Evercore ISI Initiates Coverage of OraSure Technologies With Outperform Rating Aug 21, 2020 | NEW YORK ─ Investment bank Evercore ISI said on Friday that it is initiating coverage of OraSure Technologies with an Outperform rating and a price target of $22, representing a 70 percent increase compared to its closing price of $13.15 on the Nasdaq Thursday. Then Friday Kabbom-> OraSure Technologies, Inc. (OSUR) $14.78+1.60 (+12.09%)<----- At close: August 21 4:00PM EDT/// In a note to investors on Friday, Evercore analyst Vijay Kumar and colleagues wrote that OraSure's stock price has dropped 30 percent since its earnings release on Aug. 5 when it announced a delay until the fourth quarter in the approval of a COVID-19 antigen test. "Historically, the stock has bounced back when it has had [greater than ] 30 percent corrections, [and] we see current levels as an attractive entry point," Kumar said. Kumar noted that OraSure is well positioned in the market for at-home antigen and antibody tests. "We believe the company has a core competency in developing these tests and COVID-19 falls in its wheelhouse," he said. The investment bank sees US Food and Drug Administration Emergency Use Authorization of OraSure's COVID-19 antigen test "as a meaningful catalyst over the coming months," he said. OraSure is developing a COVID-19 rapid antigen in-home self-test and an ELISA-based oral fluid COVID-19 antibody test, both of which it expects to launch in the fourth quarter. The company also sells oral fluid collection devices for COVID-19 molecular testing, which account for a large portion of its revenues. <---- OSUR is idea #2.
<Other Stocks worth following> OLLI--> $109 SIMO--> $37.70 BERY-->52.50 CHTR--> $605-->$613 GPS--> $14.40
Convalescent plasma players under pressure on FDA hold: Aug. 19, 2020 9:39 AM ET|About: Kamada Ltd. (KMDA)| delay of the expected emergency use authorization from the FDA for the treatment of COVID-19. Tons of drama here and it's confusing to me because I have heard of folks using the plasma and recovering well. Nevertheless Kamada is in an interesting position I feel to grab headlines. Why not pick a fight with the FDA you might get Trump on your side... So Kamada rocked by this I'm sure they do have an ongoing trial and If i was management I would be very keen to get some good news out and then all the press would raise the FDA hold vs Kamada's results... The FDA hold is very wobbily anyway they basically said they may flip back and I think they will. NIAID clinical director Dr. H. Clifford Lane says the authorization is on hold to allow for the review of more data since clinical trials have not proven that the plasma helps patients fight SARS-CoV-2. Recent data from the largest study to date, conducted by the Mayo Clinic, were not strong enough to support emergency use approval according to top health officials, including NIAID's Dr. Anthony Fauci. Results involving more than 35K patients showed a lower mortality rate if the convalescent plasma was administered within three days of diagnosis compared to later administration but the study has no control group so it is not possible to confirm the treatment effect. Enrollment in the study has ballooned up to an "unmanageable" level says Dr. Lane. KMDA Trial) The clinical study, which was started just recently, is sponsored by Kamada. And the data from that study, of course, will be available and will be shared in due time with the public. As we announced earlier this week, we are encouraged by the neutralization data that we have seen in the different assays that we are performing. And we just need to wait now, not too long before we have the data from the clinical study. Important to mention, the clinical study is for the less severe patients, meaning not the ones that got a compassionate use. The compassionate use is given to patients that were severely ill, while the clinical study, as we've just described, is for hospitalized but not ventilated patients. We believe that that's the right population for this type of treatment. We believe that you need to catch those patients, if I can use the term, while they're highly viral, but before their situation worsens significantly in order for IgG to be effective.<--- That Jives with one of the outcomes in the above study the FDA used for it's clinical hold... --Jefferies -- Analyst That's helpful. You also mentioned that you're looking at the product as a preventative -- potential preventative to COVID. Is there anything you can offer in terms of what that looks like? Is that a separate trial entirely? Or how do we think about the timing of that? WELL HOLY GRAIL TIME FOLKS... IF THAT WERE TO EVER HAPPEN YOU ARE LOOKING AT A $100+STOCK.... Amir London--Chief Executive Officer Yeah. So this will be a separate trial. We are now in discussions with the regulators and the KOLs in regards to that study. It's going to be the same product while the dosing might be different. We will be testing different doses in order to rate -- to get to the optimal dose for preventive or prophylactic treatment compared to sick patients. Now there are different approaches to that. You may think about the medical stuff. You may think about patients or people that were -- that are at high-risk and have been exposed to a sick COVID patient like a post-exposure prophylactic. You may think about the elderly population. So there are different opportunities, different populations, which potentially meet this criteria, and we are in advanced discussions with different relevant parties on how to design that study and to what population.